OSE Immunotherapeutics and Cenexi, a French contract development and manufacturing organization, announced the signature of an agreement whereby Cenexi will manufacture clinical batches of CoVepiT, OSE Immunotherapeutics’ vaccine candidate against COVID-19 currently in Phase 1 clinical trial, which will be used in the product’s development phases.
June 30, 2021
· 7 min read